FMC CORP 8K

FMC Corporation reported weaker Q2 2026 results and cut its full-year guidance while outlining about $1 billion of asset-sale, licensing and equity-financing transactions to reduce debt and concluding its previously announced strategic review.

On July 29, 2026, FMC Corporation reported its second quarter 2026 financial results, showing revenue of $867 million (down 17% year-over-year) and a GAAP net loss of $187 million, while adjusted EBITDA of $153 million exceeded the high end of prior guidance and operating cash flow rose sharply to $363 million due in part to a $200 million upfront licensing payment for rimisoxafen. The company lowered its full-year 2026 outlook for revenue excluding India to $3.50–$3.70 billion, adjusted EBITDA to $620–$680 million, and adjusted EPS to $1.19–$1.49, reflecting a more challenging macro environment and pricing pressure, but increased its free cash flow guidance to $75–$225 million. FMC also provided a strategic update, detailing approximately $1 billion of expected proceeds earmarked for debt reduction from a signed agreement to sell its India commercial business for $252 million, a $200 million rimisoxafen licensing deal with Corteva, a $114 million sale-leaseback of its Newark, Delaware property, and a planned $400 million equity investment by Tessenderlo Group, all subject to customary closing conditions, and announced that its Board has concluded the strategic review of options initiated in February 2026.

Filing Facts

CIK

37785

Ticker

-

Form

8K

Source Type

sec

Accession

0000037785-26-000139

Alert Tier

7